Related Experiment Video

Updated: Jul 8, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Fibrinogen genes and myocardial infarction: a haplotype analysis

Werner Koch1, Petra Hoppmann, Janita Biele

  • 1Deutsches Herzzentrum München and 1. Medizinische Klinik, Klinikum rechts der Isar, Munich, Germany. wkoch@dhm.mhn.de

Arteriosclerosis, Thrombosis, and Vascular Biology
|January 19, 2008
PubMed

Insights

Genetic variations in the fibrinogen gene region are not linked to myocardial infarction. This study found no significant association between fibrinogen gene haplotypes and heart attack risk in large case-control samples.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Biology
  • Genetic Epidemiology

Background:

  • Fibrinogen plays a role in inflammation and atherosclerosis.
  • Previous research has not definitively linked fibrinogen gene variations to myocardial infarction.

Purpose of the Study:

  • To investigate the association between haplotypes in the fibrinogen gene region and myocardial infarction.
  • To analyze genetic variations in fibrinogen-alpha, fibrinogen-beta, and fibrinogen-gamma genes.

Main Methods:

  • Haplotype analysis of tagging single nucleotide polymorphisms (SNPs) in the fibrinogen gene region.
  • Utilized two large case-control samples for myocardial infarction.
  • Examined haplotype frequencies in patients and control individuals.

Main Results:

  • No significant differences in fibrinogen gene region haplotype frequencies were observed between myocardial infarction cases and controls.
  • Analysis of haplotypes specific to individual fibrinogen genes also showed no substantial differences.
  • Haplotypes with low pairwise allelic associations did not differ significantly between groups.

Conclusions:

  • Haplotype analysis did not establish a link between genetic variations in the fibrinogen gene region and myocardial infarction.
  • The study suggests that variations in this specific gene region are unlikely to be a major determinant of myocardial infarction risk.
Abstract

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...